# US 8,277,803 B2 · Cancerous disease modifying antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,803 B2
- Document ID: US8277803B2
- Status: Granted
- Kind: B2
- Application number: 13/211,090
- Filed: 2011-08-16
- Published: 2012-01-12
- Granted: 2012-10-02
- Earliest claimed: 2007-01-23
- Assignees: Hoffman-La Roche Inc.
- Inventors: David S. F. Young; Helen P. Findlay; Susan E. Hahn; Lisa A. Popp
- Web page: https://patentgrep.com/patent/US8277803B2

## CPC

- C07K 16/30: from tumour cells
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6815: {Enzymes}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5017: {for testing neoplastic activity}
- G01N 33/57515: of the breast
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

## Claims

### Claim 1

A method for initiating antibody induced cytotoxicity of cancerous cells in a tissue sample selected from a human lung or pancreatic tumor comprising:
providing a tissue sample from said human lung or pancreatic tumor;
providing an isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 051206-01, or a humanized or chimeric version thereof; and
contacting said isolated monoclonal antibody or said humanized or chimeric antibody with said tissue sample;
wherein binding of said isolated monoclonal antibody or said humanized or chimeric antibody with said tissue sample induces cytotoxicity.

### Claim 2 (depends on 1)

The method of claim 1 wherein said isolated monoclonal antibody is contacted with said tissue sample.

### Claim 3 (depends on 2)

The method of claim 2 wherein said isolated monoclonal antibody is conjugated to a cytotoxic moiety.

### Claim 4 (depends on 3)

The method of claim 3, wherein said cytotoxic moiety is a radioactive isotope.

### Claim 5 (depends on 2)

The method of claim 2, wherein said isolated monoclonal antibody activates complement.

### Claim 6 (depends on 2)

The method of claim 2, wherein said isolated monoclonal antibody mediates antibody dependent cellular cytotoxicity.

### Claim 7 (depends on 1)

The method of claim 1, wherein said humanized version of the monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 051206-01 is contacted with said tissue sample.

### Claim 8 (depends on 7)

The method of claim 7, wherein said humanized version is conjugated to a cytotoxic moiety.

### Claim 9 (depends on 8)

The method of claim 8, wherein said cytotoxic moiety is a radioactive isotope.

### Claim 10 (depends on 7)

The method of claim 7, wherein said humanized version activates complement.

### Claim 11 (depends on 7)

The method of claim 7, wherein said humanized version mediates antibody dependent cellular cytotoxicity.

### Claim 12 (depends on 1)

The method of claim 1, wherein said chimeric version of the monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 051206-01 is contacted with said tissue sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein said chimeric version is conjugated to a cytotoxic moiety.

### Claim 14 (depends on 13)

The method of claim 13, wherein said cytotoxic moiety is a radioactive isotope.

### Claim 15 (depends on 12)

The method of claim 12, wherein said chimeric version activates complement.

### Claim 16 (depends on 12)

The method of claim 12, wherein said chimeric version mediates antibody dependent cellular cytotoxicity.
